Scandion Oncology announces modified timelines for clinical studies
Scandion Oncology A/S (“Scandion Oncology”) today announces modified timelines for the clinical Phase II colorectal cancer study and the dose range finding study for pancreatic cancer study.Due to the experience of the past half year with COVID-19 pandemic there is a modification in the timelines of the clinical Phase II colorectal cancer study and the dose range finding study for pancreatic cancer study. The timeline for the first part (dose range finding) of the ongoing colorectal cancer study that was expected to be finalized in Q4 2020, is now expected to be finalized in Q2 2021.